Seeking men and women with advanced relapsed, refractory, or resistant hematological (blood) cancer with an IDH mutation that has not responded or stopped responding to prior treatment for participation in a study of an investigational drug.
Seeking men and women whose non-small cell lung cancer responded or remained stable to platinum-based chemotherapy and are currently taking pembrolizumab for a study of an investigational drug combination for maintenance therapy.
Seeking men and women whose non-small cell lung cancer (NSCLC) has spread outside the lungs, and has a change in the gene called EGFR (epidermal growth factor receptor) and has not yet been treated for a study of an investigational drug combination.
Seeking men and women with hormone receptor positive/ human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced inoperable or metastatic breast cancer for a study of an investigational drug combination.
Seeking men and women whose non-small cell lung cancer has spread or stopped responding to treatment and whose cancer has been tested and found to have a specific mutation in the KRAS gene known as KRAS (G12C) for a study of an investigational drug for targeted treatment against the KRAS (G12C) mutation.
Seeking men and women who have been diagnosed since January 1, 2020, with metastatic non-small cell lung cancer and have been or will be treated with immunotherapy, chemotherapy or a combination of the two for a study to develop a tool to help guide treatment decisions.
Seeking men and women aged 18 and older whose non-small cell lung cancer has come back or has grown after receiving immunotherapy treatment and who are not a candidate for other biomarker-matched treatment studies for a study of an investigational drug combination.